Therapeutic approach to pain in neurodegenerative diseases: current evidence and perspectives

Canna Clinical Trials1 Comment

Neurodegenerative diseases are increasing in parallel to the lengthening of survival. The management of Alzheimer’s disease (AD) and other dementias, Parkinson’s disease (PD) and PD-related disorders, and motor neuron diseases (MND), is mainly targeted to motor and cognitive impairment, with special care for vital functions such as breathing and feeding. Emerging evidences on the possible anti-nociceptive effects of cannabis or botulinum toxin might be available soon.

Structure-Activity Relationship of Cannabis Derived Compounds for the Treatment of Neuronal Activity-Related Diseases

Canna Clinical TrialsLeave a comment

Cannabis sativa active compounds are extensively studied for their therapeutic effects, beyond the well-known psychotropic activity. C. Sativais used to treat different medical indications, such as multiple sclerosis, spasticity, epilepsy, ulcerative colitis and pain. In this review, we will consider the structure-activity relationship (SAR) of cannabinoid compounds able to bind to cannabinoid receptors and act as therapeutic agents in neuronal diseases, e.g., Parkinson’s disease.